Skip to main content
NCBI home page
Applied Microbiology logoLink to Applied Microbiology
. 1971 Jul;22(1):23–25. doi: 10.1128/am.22.1.23-25.1971

In Vitro Susceptibility of Atypical Mycobacteria To Rifampin

Abdolghader Molavi 1, Louis Weinstein 1
PMCID: PMC377370  PMID: 5111305

Abstract

Atypical mycobacteria (209 strains) were examined for susceptibility to rifampin by the proportion method by using Middlebrook 7H-10 agar. All strains of Mycobacterium kansasii and tap-water scotochromogens were inhibited by 0.25 to 1 μg of the drug per ml. Seventy-six per cent of M. scrofulaceum and 61% of M. intracellulare strains were susceptible to 4 μg/ml or less; 5% of the former and 8% of the latter were resistant to 16 μg/ml. All strains of M. gastri and M. triviale and most strains of M. terrae were sensitive to 1 to 4 μg/ml. Two strains of M. borstelense were both inhibited by 8 μg/ml. Nearly all strains of M. fortuitum were resistant to the drug. The results of this study suggest that rifampin may be a valuable agent for the treatment of many atypical mycobacterial infections.

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CANETTI G., RIST N., GROSSET J. [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol (Paris) 1963 Feb-Mar;27:217–272. [PubMed] [Google Scholar]
  2. Clark J., Wallace A. The susceptibility of mycobacteria to rifamide and rifampicin. Tubercle. 1967 Jun;48(2):144–148. doi: 10.1016/s0041-3879(67)80009-6. [DOI] [PubMed] [Google Scholar]
  3. Dans P. E., McGehee R. F., Jr, Wilcox C., Finland M. Rifampin: antibacterial activity in vitro and absorption and excretion in normal young men. Am J Med Sci. 1970 Feb;259(2):120–132. doi: 10.1097/00000441-197002000-00006. [DOI] [PubMed] [Google Scholar]
  4. Engbaek H. C., Vergmann B. Rifampicin in the treatment of drug-resistant tuberculosis. A report on 13 patients with pulmonary and one patient with renal disease. Scand J Respir Dis. 1970;51(1):11–27. [PubMed] [Google Scholar]
  5. Furesz S., Scotti R., Pallanza R., Mapelli E. Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittelforschung. 1967 May;17(5):534–537. [PubMed] [Google Scholar]
  6. Gyselen A., Verbist L., Cosemans J., Lacquet L. M., Vandenbergh E. Rifampin and ethambutol in the retreatment of advanced pulmonary tuberculosis. Am Rev Respir Dis. 1968 Dec;98(6):933–941. doi: 10.1164/arrd.1968.98.6.933. [DOI] [PubMed] [Google Scholar]
  7. Hobby GL LENERT T. F., Maier-Engallena J. Experimental observations on the antimycobacterial activity of rifampin. Proc Soc Exp Biol Med. 1969 Jun;131(2):323–326. doi: 10.3181/00379727-131-33868. [DOI] [PubMed] [Google Scholar]
  8. Lorian V., Finland M. In vitro effect of rifampin on mycobacteria. Appl Microbiol. 1969 Feb;17(2):202–207. doi: 10.1128/am.17.2.202-207.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Maggi N., Pasqualucci C. R., Ballotta R., Sensi P. Rifampicin: a new orally active rifamycin. Chemotherapy. 1966;11(5):285–292. doi: 10.1159/000220462. [DOI] [PubMed] [Google Scholar]
  10. McClatchy J. K., Waggoner R. F., Lester W. In vitro susceptibility of mycobacteria to rifampin. Am Rev Respir Dis. 1969 Aug;100(2):234–236. doi: 10.1164/arrd.1969.100.2.234. [DOI] [PubMed] [Google Scholar]
  11. Stottmeier K. D., Kubica G. P., Woodley C. L. Antimycobacterial activity of rifampin under in vitro and simulated in vivo conditions. Appl Microbiol. 1969 Jun;17(6):861–865. doi: 10.1128/am.17.6.861-865.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Vall-Spinosa A., Lester W., Moulding T., Davidson P. T., McClatchy J. K. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med. 1970 Sep 17;283(12):616–621. doi: 10.1056/NEJM197009172831202. [DOI] [PubMed] [Google Scholar]
  13. Verbist L., Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968 Dec;98(6):923–932. doi: 10.1164/arrd.1968.98.6.923. [DOI] [PubMed] [Google Scholar]
  14. Wäre M., Heinivaara O., Elo R., Tala E. Clinical experience of the treatment of drug-resistant pulmonary tuberculosis with rifampicin combined with ethambutol and capreomycin. Scand J Respir Dis Suppl. 1969;69:59–63. [PubMed] [Google Scholar]

Articles from Applied Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES